To the full analysis
U.S. Physical Therapy stock: growth
USPHU.S. Physical Therapy reported $780.99M in revenue for fiscal 2025, up 16.3% on the prior year, up 13% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
9.7%
per year from 2006 to 2025, per share 8.2%
Earnings (Annual rate)
4.7%
per year from 2006 to 2025, per share 5.2%
Free cash flow (Annual rate)
8.1%
per year from 2006 to 2025, per share 6.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 13.0% | 9.0% | 9.7% |
| Revenue per share | 9.3% | 6.8% | 8.2% |
| Earnings | −13.2% | −3.8% | 4.7% |
| Earnings per share | −19.1% | −2.2% | 5.2% |
| Free cash flow | −8.0% | 5.7% | 8.1% |
| Free cash flow per share | −11.0% | 3.6% | 6.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $135.19M | $6.3M | $13.82M |
| 2007 | $151.69M | $8.89M | $15.01M |
| 2008 | $187.69M | $10M | $25.87M |
| 2009 | $201.41M | $11.77M | $27.07M |
| 2010 | $211.23M | $15.65M | $26.85M |
| 2011 | $237.01M | $20.97M | $29.43M |
| 2012 | $252.09M | $17.93M | $35.02M |
| 2013 | $264.06M | $12.72M | $40.16M |
| 2014 | $305.07M | $19.77M | $40.03M |
| 2015 | $331.3M | $22.28M | $34.98M |
| 2016 | $356.55M | $20.55M | $42.79M |
| 2017 | $414.05M | $22.26M | $49.43M |
| 2018 | $453.91M | $10.1M | $65.81M |
| 2019 | $481.97M | $28.15M | $52.26M |
| 2020 | $422.97M | $30.56M | $92.36M |
| 2021 | $495.02M | $27.82M | $68.21M |
| 2022 | $553.14M | $28.27M | $50.29M |
| 2023 | $604.8M | $14.67M | $72.68M |
| 2024 | $671.35M | $26.46M | $65.75M |
| 2025 | $780.99M | $15.06M | $60.99M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.